ArticleFrontiers in medicine2025
Gallbladder and biliary tract cancer burdens in China from 1990 to 2021 and projection to 2044: findings from the 2021 Global Burden of Disease study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Burden of gallbladder and biliary tract cancer (GBTC) in the middle east and North Africa (MENA) from 1990 to 2021: from the global burden of disease (GBD).Annals of medicine and surgery (2012) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gallbladder and biliary tract cancers (GBTCs) have high incidence and mortality rates in China, imposing a substantial disease burden. Establishing comprehensive strategies is crucial for alleviating this burden. We report the average estimated annual percentage change (EAPC) in age-standardized rates (ASRs) of GBTCs globally and in China via Global Burden of Disease (GBD) study 2021 data and the relationships of GBTCs with body mass index (BMI) and the sociodemographic index (SDI). The 2021-2044 GBTCs prevalence trends were predicted by sex. Methods: We collected and analyzed GBD data from 1990 to 2021, including incidence, prevalence, deaths, disability-adjusted life years (DALYs), and age-standardized incidence (ASIR), prevalence (ASPR), mortality (ASMR), and DALYs (ASDR) rates and calculated the proportion of deaths and DALYs attributable to risk factors by sex. Future trends from 2022 to 2044 were predicted with Nordpred age-period-cohort models. Results: The number of GBTCs-related incident cases, prevalent cases, deaths, and DALYs increased from 1990 to 2021. However, the GBTCs-related ASMR and ASDR decreased during the same period. These changes may be related to risk factors, such as increased BMI. Furthermore, we used the projection model to estimate that the GBTCs-related ASPR in all populations will steadily increase, whereas the GBTCs-related ASMR and ASDR are expected to significantly decline until 2044. Conclusion: The increasing GBTCs prevalence in China due to SDI advancements and population aging underscores the importance of early monitoring and prevention measures to alleviate the disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.